1) Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-61.
2) Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 2018; 14(5): 270-84.
3) Murphy MK, Hall JE, Adams JM, Lee H, Welt CK. Polycystic ovarian morphology in normal women does not predict the development of polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91: 3878-84.
4) Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6-15.
5) Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-5.
6) Sohaei S, Amani R, Tarrahi MJ, Ghasemi-Tehrani H. The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovarysyndrome: A randomized, double-blind, placebo-controlled clinical trial. Complement Ther Med. 2019 Dec;47:102201. doi: 10.1016/j.ctim.2019.102201
7) Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, Hatzistilianou M, Katsikis I, Panidis D. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008; 196: 958-65.
8) Boger RH, Maas R, Schulze F, Schwedhelm E. Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality. Clin Chem Lab Med 2005; 43: 1124-9.
9) Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T, Cooke JP. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-6.
10) Nacul A.P, Andrade C.D, Schwarz P., Homem de Bittencourt P.I., Spritzer P.M. Nitric oxide and fibrinogen in polycystic ovary syndrome: Associations with insülin resistance and obesity. Eur J Obs Gynecol Rep Biol. 2007; 133: 191-6.
11) Folsom AR, Pankow JS, Williams RR, Evans GW, Province MA, Eckfeldt JH. Fibrinogen, plasminogen activator inhibitor-1, and carotid intima-media wall thickness in the NHLBI Family Heart Study. Thromb Haemost. 1998; 79: 400-4.
12) Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002; 87: 3871-5.
13) Ozgurtas T, Oktenli CI, Dede M, Tapan S, Kenar L, Sanisoglu SY, Yesilova Z, Yenen MC, Erbil MK, Baser I. Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). Atherosclerosis. 2008; 200: 336-44.
14) Lindahl B, Asplund K, Eliasson M, Evrin P. Insulin resistance syndrome and fibrinolytic activity: The Northern Sweden MONICA study. Int J Epidemiol 1996; 25: 291-9.
15) Lakhani K, Leonard A, Seifalian AM, Hardiman P. Microvascular dysfunctioin women with polycystic ovary syndrome. Hum Reprod 2005; 20: 3219-24.
16) Meng C. Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): A meta-analysis. J Int Med Res 2019; 47(9): 4083-94.
17) Krishnaa MB, Josepha A, Thomasa PL, Dsilva B, Pillai SM, Laloraya M. Impaired Arginine Metabolism Coupled to a Defective Redox Conduit Contributes to Low Plasma Nitric Oxide in Polycystic Ovary Syndrome. Cell Physiol Biochem 2017; 43: 1880-92.
18) Szczuko M, Zapałowska-Chwyc M, Drozd A, Maciejewska D, Starczewski A, Stachowska E. Effect of IGF-I and TNF-α on intensification of steroid pathways in women with PCOS phenotypes are not identical. Enhancement of progesterone pathway in women with PCOS increases the concentration of TNF-α. Gynecol Endocrinol 2016; 32(9): 714-7.
19) Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson SK Jr. Carotid atherosclerosis in women with polycystic ovary syndrome: Initial results from a case-control study. Am J Obstet Gynecol. 1996; 174: 1224-9.
20) Talbott E.O, Zborowski J.V., Sutton-Tyrrell K., McHugh-Pemu K.P., Guzick D.S. Cardiovascular Risk in Women with Polycystic Ovary Syndrome. Obs Gynecol Clin North America. 2001; 28: 111-29.
21) Rashidi BH, Gorginzadeh M, Aalipour S, Sills ES. Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center. Arch Endocrinol Metab. 2016; 60(5): 486-491.
22) Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19-25.
23) Chen GF, Wagner L, Sasser JM, Zharikov S, Moningka NC, Baylis C. Effects of angiotensin type 1 receptor blockade on arginine and ADMA synthesis and metabolic pathways in fawn-hooded hypertensive rats. Nephrol Dial Transplant. 2010; 25: 3518-25.
24) Walch K, Kolbus A, Hefler-Frischmuth K. Polymorphisms of the endothelial nitric oxide synthase gene in premenopausal women with polycystic ovary syndrome. Maturitas. 2008; 61: 256-9.
25) Ngo DTM, Chan WP, Rajendran S, Heresztyn T, Amarasekera A, Sverdlov AL, O’Loughlin PD, Morris HA, Chirkov YY, Norman RJ, Horowitz JD. Determinants of insulin responsiveness in young women: Impact of polycystic ovarian syndrome, nitric oxide, and vitamin D. Nitric Oxide. 2011; 25: 326-30.
26) Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-21.
27) Lakhani K, Hardiman P, Seifalian AM. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 2004; 175: 353-9.
28) Cibula D, Cifkova R, Fanta M, et a1 Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000; 15: 785-9.
29) Talbott EO, Zborowski JV, Rager JR, BoudreauxMY, EdmundowiczDA, Guzick DS. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 5454-61.
30) Pamuk B.O, Torun A.N, Kulaksizoglu M, Ertugrul D, Ciftci O, Kulaksizoglu S, Yildirim E, Demirag N.G. Asymmetric dimethyl-arginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertility and Sterility. 2010; 93: 1227-33.
31) Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-74.
32) Mai K, Bobbert T, Reinecke F, Andres J, Maser-Gluth C, Wudy SA, Mohlig M, Weickert MO, Hartmann MF, Schulte HM, Diederich S, Pfeiffer AFH, Spranger J. Intravenous Lipid and Heparin Infusion-Induced Elevation in Free Fatty Acids and Triglycerides Modifies Circulating Androgen Levels in Women: A Randomized, Controlled Trial. J Clin Endocrinol Metab. October 2008, 93: 3900-6.
33) Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S, Mittermayer F, Wolzt M, Krzyzanowska K, Randeva H, Schernthaner G, Lehnert H. Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in Women with Polycystic Ovary Syndrome before and after Metformin Treatment. J Clin Endocrinol Metab. January 2008, 93(1): 82-90.
34) Dagre A, Lekakis J, Mihas C, Protogerou A, Thalassinou L, Tryfonopoulos D, Douridas G, Papamichael C, Alevizaki M. Association of dehydroepiandrosterone- sulfate with endothelial function in young women with polycystic ovary syndrome. Eur J Endocrinol 2006; 154: 883-90.
35) Dereli D, Ozgen G, Buyukkececi F, Guney E, Yilmaz C. Platelet dysfunction in lean women with polycystic ovary syndrome and association with insulin sensitivity. J Clin Endocrinol Metab 2003; 88: 2263-8.
36) Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
37) Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, Schernthaner G. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042-7.
38) Mohlig M, Spranger J, Osterhoff M, Ristow M, Pfeiffer AF, Schill T, Schlosser HW, Brabant G, Schofl C. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 2004; 150: 525-32.
39) Tempfer C, Unfried G, Zeillinger R, Hefler L, Nagele F, Huber J. Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. Hum Reprod 2001; 16: 1644-7.
40) Demir B, Pasa S, Demir S, Buyukkaya R, Atay AE, Atamer Y, Gul T. Morphologic and functional vascular alterations in patients with polycystic ovary syndrome. Clin Exp Obstet Gynecol 2011; 38(4): 401-4.
41) Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide. 2000; 4(4): 441-58.
42) Demirel F, Bideci A, Cinaz P, Camurdan MO, Biberoglu G, Yesilkaya E, Hasanoglu A. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007; 67: 129-34.
43) Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-8.
44) Mather KJ, Verma S, Coreblum B, Anderson TJ. Normal endothelial function despite insulin resistance in health women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85: 1851-6.
45) Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab 2004; 89: 6277-81.